Knowledge and Perceptions Towards Cardiovascular Disease Prevention Among Patients with Type 2 Diabetes Mellitus: A Review of Current Assessments and Recommendations

Page: [503 - 511] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Introduction: Patients with type 2 diabetes mellitus (T2DM) are at significantly higher risk of developing cardiovascular diseases (CVD). There is a scarcity of literature reviews that describe and summarize T2DM patients' knowledge and perception about CVD prevention.

Objectives: To describe and summarize the assessment of knowledge and perceptions about CVD risk and preventive approaches among patients with T2DM.

Methods: A scoping review methodology was adopted, and three scientific databases, Google Scholar, Science Direct, and PubMed were searched using predefined search terms. A multistage screening process that considered relevancy, publication year (2009-2019), English language, and article type (original research) was followed. We formulated research questions focused on the assessment of levels of knowledge and perceptions of the illness relevant to CVD prevention and the identification of associated patients' characteristics.

Results: A total of 16 studies were included. Patients were not confident to identify CVD risk and other clinical consequences that may occur in the prognostic pathway of T2DM. Furthermore, patients were less likely to identify all CV risk factors indicating a lack of understanding of the multi-- factorial contribution of CVD risk. Patients' beliefs about medications were correlated with their level of adherence to medications for CVD prevention. Many knowledge gaps were identified, including the basic disease expectations at the time of diagnosis, identification of individuals' CVD risk factors, and management aspects. Knowledge and perceptions were affected by patients' demographic characteristics, e.g., educational level, race, age, and area of residence.

Conclusion: There are knowledge gaps concerning the understanding of CVD risk among patients with T2DM. The findings necessitate educational initiatives to boost CVD prevention among patients with T2DM. Furthermore, these should be individualized based on patients' characteristics, knowledge gaps, disease duration, and estimated CVD risk.

Keywords: Knowledge, perception, type 2 diabetes mellitus, diabetic patient, cardiovascular disease, risk prevention.

[1]
Ahmed KA, Muniandy S, Ismail IS. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomed Res 2010; 21(2)
[2]
MEMS. MOH, Academy of Medicine Malaysia DM, et al Clinical Practice Guideline for Management of Type 2 Diabetes Mellitus. (5th ed.), Putrajaya: Ministry of Health Malaysia 2015.
[3]
Unachukwu C, Ofori S. Diabetes Mellitus And Cardiovascular Risk Internet J Endocrinol
[4]
Piepoli MF, Hoes AW, Agewall S, et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37(29): 2315-81.
[http://dx.doi.org/10.1093/eurheartj/ehw106] [PMID: 27222591]
[5]
Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014; 142(3): 375-415.
[http://dx.doi.org/10.1016/j.pharmthera.2014.01.003] [PMID: 24462787]
[6]
Martell-Claros N, Aranda P, González-Albarrán O, et al. Perception of health and understanding of cardiovascular risk among patients with recently diagnosed diabetes and/or metabolic syndrome. Eur J Prev Cardiol 2013; 20(1): 21-8.
[http://dx.doi.org/10.1177/1741826711423114] [PMID: 21947492]
[7]
Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ 2011; 37(6): 801-12.
[http://dx.doi.org/10.1177/0145721711423980] [PMID: 22021025]
[8]
Broadbent E, Donkin L, Stroh JC. Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients. Diabetes Care 2011; 34(2): 338-40.
[http://dx.doi.org/10.2337/dc10-1779] [PMID: 21270191]
[9]
Welschen LMC, Bot SDM, Kostense PJ, et al. Effects of cardiovascular disease risk communication for patients with type 2 diabetes on risk perception in a randomized controlled trial: the @RISK study. Diabetes Care 2012; 35(12): 2485-92.
[http://dx.doi.org/10.2337/dc11-2130] [PMID: 22923669]
[10]
Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract 2011; 93(1): 1-9.
[http://dx.doi.org/10.1016/j.diabres.2011.02.002] [PMID: 21382643]
[11]
Arksey H, O’Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol Theory Pract 2005; 8: 19-32.
[http://dx.doi.org/10.1080/1364557032000119616]
[12]
Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci 2010; 5: 69.
[http://dx.doi.org/10.1186/1748-5908-5-69] [PMID: 20854677]
[13]
Gazmararian JA, Ziemer DC, Barnes C. Perception of barriers to self-care management among diabetic patients. Diabetes Educ 2009; 35(5): 778-88.
[http://dx.doi.org/10.1177/0145721709338527] [PMID: 19556552]
[14]
Aikens JE, Piette JD. Diabetic patients’ medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments. Diabetes Care 2009; 32(1): 19-24.
[http://dx.doi.org/10.2337/dc08-1533] [PMID: 18852334]
[15]
Lu S, Harris MF. Prevention of diabetes and heart disease -- patient perceptions on risk, risk assessment and the role of their GP in preventive care. Aust Fam Physician 2013; 42(5): 328-31.
[PMID: 23781536]
[16]
Petriček G, Vrcić-Keglević M, Vuletić G, Cerovecki V, Ozvacic Z, Murgic L. Illness perception and cardiovascular risk factors in patients with type 2 diabetes: cross-sectional questionnaire study. Croat Med J 2009; 50(6): 583-93.
[http://dx.doi.org/10.3325/cmj.2009.50.583] [PMID: 20017227]
[17]
Elnaem MH, Mohamed MHN, Huri HZ, Shah ASM. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Ther Clin Risk Manag 2019; 15: 137-45.
[http://dx.doi.org/10.2147/TCRM.S182716] [PMID: 30705590]
[18]
Elnaem MH, Nik Mohamed MH, Huri HZ, et al. Patterns of statin therapy prescribing among hospitalized patients with Type 2 diabetes mellitus in two Malaysian tertiary hospitals. Trop J Pharma Res. 2017; 16 (12): 3005-3011.
[19]
Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. BMJ 2016; 353: i3305.
[http://dx.doi.org/10.1136/bmj.i3305] [PMID: 27353261]
[20]
Aflakseir A. Role of illness and medication perceptions on adherence to medication in a group of Iranian patients with type 2 diabetes. J Diabetes 2012; 4(3): 243-7.
[http://dx.doi.org/10.1111/j.1753-0407.2012.00183.x] [PMID: 22221835]
[21]
Stark Casagrande S, Ríos Burrows N, Geiss LS, Bainbridge KE, Fradkin JE, Cowie CC. Diabetes knowledge and its relationship with achieving treatment recommendations in a national sample of people with type 2 diabetes. Diabetes Care 2012; 35(7): 1556-65.
[http://dx.doi.org/10.2337/dc11-1943] [PMID: 22498806]
[22]
Zehirlioglu L, Mert H, Sezgin D, Özpelit E. Cardiovascular risk, risk knowledge, and related factors in patients with type 2 diabetes. Clin Nurs Res 2020; 29(5): 322-30.
[http://dx.doi.org/10.1177/1054773819844070] [PMID: 31023065]
[23]
Tsuji M, Arima H, Ohkubo T, et al. Socioeconomic status and knowledge of cardiovascular risk factors: Nippon data2010. J Epidemiol 2018; 28(Suppl. 3): S46-52.
[http://dx.doi.org/10.2188/jea.JE20170255] [PMID: 29503386]
[24]
Deepa M, Bhansali A, Anjana RM, et al. Knowledge and awareness of diabetes in urban and rural India: The Indian Council of Medical Research India Diabetes Study (Phase I): Indian Council of Medical Research India Diabetes 4. Indian J Endocrinol Metab 2014; 18(3): 379-85.
[http://dx.doi.org/10.4103/2230-8210.131191] [PMID: 24944935]
[25]
Abubakari A-R, Jones MC, Lauder W, et al. Ethnic differences and socio-demographic predictors of illness perceptions, self-management, and metabolic control of type 2 diabetes. Int J Gen Med 2013; 6: 617-28.
[http://dx.doi.org/10.2147/IJGM.S46649] [PMID: 23935384]
[26]
Lynch EB, Fernandez A, Lighthouse N, Mendenhall E, Jacobs E. Concepts of diabetes self-management in Mexican American and African American low-income patients with diabetes. Health Educ Res 2012; 27(5): 814-24.
[http://dx.doi.org/10.1093/her/cys058] [PMID: 22641792]
[27]
Nanayakkara N, Ranasinha S, Gadowski A, et al. Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes. J Diabetes Complications 2018; 32(3): 279-90.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.11.009] [PMID: 29352694]
[28]
Goff DC, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and rationale for the action to control cardiovascular risk in diabetes (accord) trial. Am J Cardiol 99(12A): 4i-20i.
[29]
Mosnier-Pudar H, Hochberg G, Eschwege E, et al. How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS survey. Diabetes Metab 2009; 35(3): 220-7.
[http://dx.doi.org/10.1016/j.diabet.2009.02.001] [PMID: 19303338]
[30]
Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122(8): 844-6.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.960138] [PMID: 20733112]
[31]
Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122(8): 847-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.960120] [PMID: 20733113]
[32]
Martinez-Hervas S, Carmena R, Ascaso JF. Significance of LDL-C lowering therapy in diabetic patients. Clin Lipidol 2011; 6: 389-99.
[http://dx.doi.org/10.2217/clp.11.28]
[33]
Karlson BW, Barter PJ, Palmer MK, Lundman P, Nicholls SJ. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutr Metab Cardiovasc Dis 2012; 22(9): 697-703.
[http://dx.doi.org/10.1016/j.numecd.2012.03.003] [PMID: 22705128]
[34]
Riddle MC, Karl DM. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care 2012; 35(10): 2100-7.
[http://dx.doi.org/10.2337/dc12-0650] [PMID: 22996182]
[35]
Fung V, Graetz I, Reed M, Jaffe MG. Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. PLoS One 2018; 13(2): e0191817.
[http://dx.doi.org/10.1371/journal.pone.0191817] [PMID: 29420613]
[36]
Elnaem MH, Rosley NFF, Alhifany AA, Elrggal ME, Cheema E. Impact of Pharmacist-Led Interventions on Medication Adherence and Clinical Outcomes in Patients with Hypertension and Hyperlipidemia: A Scoping Review of Published Literature. J Multidiscip Healthc 2020; 13: 635-45.
[http://dx.doi.org/10.2147/JMDH.S257273] [PMID: 32764955]